B effector cells activated by a chimeric protein consisting of IL-2 and the ectodomain of TGF-β receptor II induce potent antitumor immunity

Cancer Research

Volumn 72, Issue 5, 2012, Pages 1210-1220

  Penafuerte, Claudia ^a,b   Ng, Spencer ^c   Bautista Lopez, Norma ^b   Birman, Elena ^b   Forner, Kathy ^b   Galipeau, Jacques ^b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CHIMERIC PROTEIN; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR; OVALBUMIN; SMAD7 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; TRANSCRIPTION FACTOR PAX5; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE ACTIVATION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER REGRESSION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; FEMALE; GENE OVEREXPRESSION; IN VITRO STUDY; LYMPHOCYTE TRANSFORMATION; LYMPHOMA; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ANIMALS; ANTIGEN-PRESENTING CELLS; B-LYMPHOCYTE SUBSETS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENE KNOCKOUT TECHNIQUES; HUMANS; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; RECOMBINANT FUSION PROTEINS;

EID: 84857748785     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-1659     Document Type: Article

References (27)

1. Steinman RM. The dendritic cell system and its role in immunogenicity. Ann Rev Immunol 1991;9:271-96.
2. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-8. (Pubitemid 26028073)
3. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32. (Pubitemid 28144092)
4. Siena S, Di NM, Bregni M, Mortarini R, Anichini A, Lombardi L, et al. Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. Exp Hematol 1995;23:1463-71. (Pubitemid 26035713)
5. Ardeshna KM, Pizzey AR, Thomas NS, Orr S, Linch DC, Devereux S. Monocyte-derived dendritic cells do not proliferate and are not susceptible to retroviral transduction. Br J Haemato 2000;108:817-24. (Pubitemid 30304515)
6. Harris DP, Haynes L, Sayles PC, Duso DK, Eaton SM, Lepak NM, et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 2000;1:475-82.
7. Harris DP, Goodrich S, Mohrs K, Mohrs M, Lund FE. Cutting edge: the development of IL-4-producing B cells (B effector 2 cells) is controlled by IL-4, IL-4 receptor alpha, and Th2 cells. J Immunol 2005;175:7103-7. (Pubitemid 41713402)
8. Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature 1985;314:537-9. (Pubitemid 15124262)
9. Rock KL, Benacerraf B, Abbas AK. Antigen presentation by hapten-specific B lymphocytes. I. Role of surface immunoglobulin receptors. J Exp Med 1984;160:1102-13. (Pubitemid 14020970)
10. Ke Y, Kapp JA. Exogenous antigens gain access to the major histocompatibility complex class I processing pathway in B cells by receptor-mediated uptake. J Exp Med 1996;184:1179-84.
11. Barnaba V, Franco A, Alberti A, Benvenuto R, Balsano F. Selective killing of hepatitis B envelope antigen-specific B cells by class I-restricted, exogenous antigen-specific T lymphocytes. Nature 1990; 345:258-60.
12. Ahmadi T, Flies A, Efebera Y, Sherr DH. CD40 Ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I- and class II-binding peptides. Immunology 2008;124:129-40. (Pubitemid 351537580)
13. Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung K, Daley J, et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 1997;100:2757-65. (Pubitemid 28007544)
14. Penafuerte C, Bautista-Lopez N, Bouchentouf M, Birman E, Forner K, Galipeau J. Novel TGF-beta antagonist inhibits tumor growth and angiogenesis by inducing IL-2 receptor-driven STAT1 activation. J Immunol 2011;186:6933-44.
15. Piskurich JF, Lin KI, Lin Y, Wang Y, Ting JP, Calame K. BLIMP-I mediates extinction of major histocompatibility class II transactivator expression in plasma cells. Nat Immunol 2000;1:526-32.
16. Shaffer AL, Lin KI, Kuo TC, Yu X, Hurt EM, Rosenwald A, et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 2002;17:51-62. (Pubitemid 34874618)
17. Diehl SA, Schmidlin H, Nagasawa M, van Haren SD, Kwakkenbos MJ, Yasuda E, et al. STAT3-mediated up-regulation of BLIMP1 is coordinated with BCL6 down-regulation to control human plasma cell differentiation. J Immunol 2008;180:4805-15.
18. Scheeren FA, Naspetti M, Diehl S, Schotte R, Nagasawa M, Wijnands E, et al. STAT5 regulates the self-renewal capacity and differentiation of human memory B cells and controls Bcl-6 expression. Nat Immunol 2005;6:303-13. (Pubitemid 41724768)
19. Lomo J, Blomhoff HK, Beiske K, Stokke T, Smeland EB. TGF-beta 1 and cyclic AMP promote apoptosis in resting human B lymphocytes. J Immunol 1995;154:1634-43.
20. Dong Y, Tang L, Letterio JJ, Benveniste EN. The Smad3 protein is involved in TGF-beta inhibition of class II transactivator and class II MHC expression. J Immunol 2001;167:311-9. (Pubitemid 32567794)
21. Jenkins BJ, Grail D, Nheu T, Najdovska M, Wang B, Waring P, et al. Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signaling. Nat Med 2005;11:845-52. (Pubitemid 41161116)
22. Zhang S, Fei T, Zhang L, Zhang R, Chen F, Ning Y, et al. Smad7 antagonizes transforming growth factor beta signaling in the nucleusby interfering with functional Smad-DNA complex formation. Mol Cell Biol 2007;27:4488-99. (Pubitemid 46906571)
23. Itoh S, ten DP. Negative regulation of TGF-beta receptor/Smad signal transduction. Curr Opin Cell Biol 2007;19:176-84. (Pubitemid 46386411)
24. Harris DP, Goodrich S, Gerth AJ, Peng SL, Lund FE. Regulation of IFN-gamma production by B effector 1 cells: essential roles for T-bet and the IFN-gamma receptor. J Immunol 2005;174:6781-90. (Pubitemid 40705641)
25. Wang S. TRAIL: a sword for killing tumors. Curr Med Chem 2010;17:3309-17.
26. Blanca IR, Bere EW, Young HA, Ortaldo JR. Human B cell activation by autologous NK cells is regulated by CD40-CD40 ligand interaction: role of memory B cells and CD5+ B cells. J Immunol 2001;167:6132-9. (Pubitemid 33081539)
27. Lenz P, Gessner JE, Sautes C, Schmidt RE. Fc gamma-receptor III (CD 16) is involved in NK-B cell interaction. Immunobiology 1996;196:387-98. (Pubitemid 27075955)